ライフサイエンスコーパス: neutropenia

1 chronic G-CSF therapy to reverse the severe neutropenia.

2 ancestry, due in part to increased rates of neutropenia.

3 ts but does not affect cytopenias other than neutropenia.

4 obability of remaining infection-free during neutropenia.

5 obability of remaining infection-free during neutropenia.

6 0%; P < .001) mainly because of asymptomatic neutropenia.

7 a result of intestinal translocation during neutropenia.

8 neutropenia; 10 patients (9.3%) had febrile neutropenia.

9 , and three discontinued because of moderate neutropenia.

10 r predicting infectious complications during neutropenia.

11 effective treatment for chemotherapy-induced neutropenia.

12 All bIFIs occurred during periods of neutropenia.

13 h levofloxacin was recommended during severe neutropenia.

14 r predicting infectious complications during neutropenia.

15 infections, graft and patient survival, and neutropenia.

16 s not expected to result in prolonged severe neutropenia.

17 higher dose of corticosteroids, or prolonged neutropenia.

18 th of neutrophil precursors and resulting in neutropenia.

19 3), hemolysis (1), thrombocytopenia (4), and neutropenia (1).

20 evalence of anemia (6.9% vs 3.4%, P < .001), neutropenia (1.3% vs 0.2%, P < .001), and thrombocytopen

21 infections (24%), anemia (12%), and febrile neutropenia (10%).

22 n >=10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia.

23 eutropenia (340 [15%] vs 328 [15%]), febrile neutropenia (112 [5%] vs 142 [6%]), and leucopenia (62 [

24 rade 3 or 4 adverse event in both groups was neutropenia (112 [53%] of 212 patients in the venetoclax

25 or 4 treatment-emergent adverse events were neutropenia (116 [42%] of 278 patients vs 23 [9%] of 270

26 reported, irrespective of attribution, were neutropenia (117 [66%] of 177 participant cycles in the

27 r worse were neutropenia (20 [30%]), febrile neutropenia (12 [18%]), and thrombocytopenia (six [9%]).

28 cluded febrile neutropenia (16 [41%] of 39), neutropenia (12 [31%]), thrombocytopenia (13 [33%]), ana

29 and octreotide, they included fatigue (27%), neutropenia (12%), and nausea (6%).

30 mergent adverse events during induction were neutropenia (12.9%) and infection (9.2%).

31 e 3 or 4 adverse events in either group were neutropenia (124 [51%] of 244 patients in the tucidinost

32 thrombocytopenia (18 [41%] of 44 patients), neutropenia (13 [30%]), anaemia (11 [25%]), leukopenia (

33 %; difference, <1% [95% CI, -4% to 4%]), and neutropenia (13% vs 10%; difference, 3% [95% CI, -5% to

34 Patients with baseline neutropenia 14-90 days before COVID-19 diagnosis had wor

35 rophil count (31 [12%] vs 27 [11%]), febrile neutropenia (14 [6%] vs 16 [6%]), diarrhoea (12 [5%] vs

36 >=3 AEs (occurring in >=5% of patients) were neutropenia (14%), pneumonia (11%), hypertension (7%), a

37 28 days (32%), infections (20%), and febrile neutropenia (14%).

38 tients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%]) in the pazopanib group, and neutr

39 s were leukopenia (16 [43%] of 37 patients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%

40 atment-related grade 3-4 adverse events were neutropenia (15 [50%] of 30 patients), increased alanine

41 cytopenia (30%), hypertension (15%), febrile neutropenia (15%), and lung infection (11%).

42 e patient at least possibly related included neutropenia (15.9%), thrombocytopenia (11.1%), and pneum

43 patients receiving R-pola (most common were neutropenia [15%] and diarrhoea [10%]; one grade 5 adver

44 s arm B were 13 (48%) versus seven (30%) for neutropenia, 15 (55%) versus two (9%) for thrombocytopen

45 worse treatment-related adverse events were neutropenia (152 [32%] of 473 in the atezolizumab plus c

46 grade 3 or 4 adverse events included febrile neutropenia (16 [41%] of 39), neutropenia (12 [31%]), th

47 s occurring in more than 5% of patients were neutropenia (17 [16%] of 106 patients) and pneumonia (7

48 ies were fever/infection (18 [35.3%] of 51), neutropenia (17 [33.3%] of 51), pain (15 [29.4%] of 51),

49 %] of 265 patients in the placebo group) and neutropenia (17 [7%] of 258 vs six [2%] of 265).

50 otransferase), maculopapular rash (17%), and neutropenia (17%).

51 31%] of 83, and 19 [24%] of 83 patients) and neutropenia (18 [23%], 13 [16%], and six [8%]).

52 ts taking CVD were haematological, including neutropenia (18 [7%] patients), thrombocytopenia (19 [7%

53 -related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (

54 rade 3-4 leucopenia, 148 (82%) had grade 3-4 neutropenia, 19 (10%) had anaemia, two (1%) had thromboc

55 mmon adverse events of grade 3 or worse were neutropenia (20 [30%]), febrile neutropenia (12 [18%]),

56 The most common grade 3-4 adverse event was neutropenia (200 [49%] of 408 patients in the pertuzumab

57 gent adverse event in groups A, B, and C was neutropenia (21 [27%] of 78 patients, 17 [22%] of 77, an

58 dverse events were anaemia (22 [73%] of 34), neutropenia (21 [70%]), and thrombocytopenia (18 [60%])

59 (31%), lymphopenia (24%), anemia (21%), and neutropenia (21%).

60 ocetaxel, fever (18 [12%] and 19 [15%]), and neutropenia (22 [14%] and ten [8%]).

61 common grade 3-4 adverse events were febrile neutropenia (22 [66%]), bloodstream infections (six [16%

62 e events occurring in > 10% of patients were neutropenia (22%), anemia (13%), thrombocytopenia (13%),

63 55%]) and anaemia (17 [52%]) in group 2; and neutropenia (23 [66%] of 35), thrombocytopenia (22 [63%]

64 % vs 22% of patients), mainly represented by neutropenia (23% vs 7%).

65 patients receiving R-pola (most common were neutropenia [23%], anaemia [8%] and diarrhoea [8%]; no g

66 h ramucirumab than with placebo were febrile neutropenia (24 [9%] of 258 patients in the ramucirumab

67 or greater TEAE, the most common TEAEs were neutropenia (24.8%), diarrhea (14.7%), anemia (14.7%), a

68 or 4 treatment-emergent adverse events were neutropenia (25 [10%] of 242 treated with doxorubicin-lo

69 ead to nevirapine cessation in any neonates; neutropenia (25 [6%] neonates) and anaemia (six [1%]) we

70 ble thrombocytopenia (28 [62%] patients) and neutropenia (26 [58%]), and non-haematological toxicity

71 erious adverse events recorded, were febrile neutropenia (27 [17%] of 155 serious adverse events in p

72 and thrombocytopenia (18 [60%]) in group 1; neutropenia (27 [82%] of 33), thrombocytopenia (18 [55%]

73 common grade 3 or worse adverse events were neutropenia (272 [81%] of 336 patients in the veliparib

74 most common grade 3 or 4 adverse events were neutropenia (28% vs 15%), lymphopenia (17% vs 10%), and

75 EAEs) were diarrhea (48.8%), nausea (29.5%), neutropenia (28.7%), fatigue (27.9%), and cough (27.1%).

76 a (46%), thrombocytopenia (38%), and febrile neutropenia (29%).

77 patients receiving R-pina (most common were neutropenia [29%] and hyperglycaemia [10%]; nine [21%] g

78 patients receiving R-pina (most common were neutropenia [29%] and hyperglycaemia [14%]; no grade 5 a

79 nation group), anaemia (3 [4%] vs 19 [23%]), neutropenia (3 [4%] vs 13 [16%]), and thrombocytopenia (

80 grade 3 or 4 adverse event in both arms was neutropenia (30.9% with ganetespib and docetaxel v 25% w

81 events (>=10% in either group) were febrile neutropenia (31 [42%] vs 28 [39%]), decreased white bloo

82 nd D were anemia (12% and 7%, respectively), neutropenia (32% and 30%, respectively), thrombocytopeni

83 adverse events were thrombocytopenia (47%), neutropenia (32%), anemia (27%), leukopenia (16%), fatig

84 ] of 258 patients in the intravenous group), neutropenia (34 [13%] and 20 [8%]), and thrombocytopenia

85 chemotherapy in 5% or more of patients were neutropenia (34 [13%] of 252 patients in the intravenous

86 Grade 3 to 4 adverse events included neutropenia (34%), lymphopenia (32%), infection (22%), a

87 nosumab vs 2218 patients with placebo), were neutropenia (340 [15%] vs 328 [15%]), febrile neutropeni

88 worse treatment-emergent adverse events were neutropenia (35 [18%] of 193 patients in the venetoclax

89 4 toxicities were neutropenia (62%), febrile neutropenia (35%), and peripheral sensory neuropathy (24

90 ction (16.9% v 10.7%, respectively), febrile neutropenia (35.0% v 17.7%, respectively), mucositis (8.

91 lenalidomide were haematological, including neutropenia (362 [33%] patients), thrombocytopenia (72 [

92 he most common grade 3-4 adverse events were neutropenia (38 [8%] of 453 patients in the atezolizumab

93 gent adverse events of grade 3 or worse were neutropenia (39 [48%] of 81 patients), thrombocytopenia

94 logic toxicities with regimen M were febrile neutropenia (39.2%) and infections (21.6%).

95 The most common were neutropenia (4%), thrombocytopenia (3%), and increased l

96 ] of 329 patients in the standard group) and neutropenia (40 [12%] vs 73 [22%]).

97 he most common grade 3-4 adverse events were neutropenia (40 [28%] of 141 patients) and anaemia (32 [

98 including incidence and severity of febrile neutropenia (41 [18%] patients in the A+CHP group and 33

99 mon adverse events of grade 3 and above were neutropenia (41 [56%] of 73) and thrombocytopenia (17 [2

100 most common grade 3 to 4 toxicities included neutropenia (41%), thrombocytopenia (30%), hypertension

101 ade 3 or greater adverse events were febrile neutropenia (42%), thrombocytopenia (38%), and WBC count

102 s were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%]).

103 of grade >= 3 during cycle 1 included fever/neutropenia (45%), infection (47%), and rash (40%).

104 8%; P = .007), and higher rates of grade 3/4 neutropenia (45.8% v 21.5%; P < .001), febrile neutropen

105 adverse events regardless of causality were neutropenia (46%), thrombocytopenia (38%), and febrile n

106 s 65 [21%] of 308 in the doxorubicin group), neutropenia (47 [15%] vs 92 [30%]), febrile neutropenia

107 rombocytopenia (62.0%), hypokalemia (49.3%), neutropenia (47.9%), and peripheral edema (45.1%).

108 gible participants who began treatment, were neutropenia (48 [15%]), low serum albumin (33 [10%]), we

109 nine [9%] patients), leucopenia (30 [29%]), neutropenia (48 [46%]), and thrombocytopenia (seven [7%]

110 arm: CD4 lymphopenia (8% v 0%; P = .06) and neutropenia (49% v 32%; P = .08), but treatment delivery

111 t common adverse events of grade 3 or 4 were neutropenia (50.0% in the daratumumab group vs. 35.3% in

112 emergent adverse events (AEs), most commonly neutropenia (51%), infections (24%), anemia (12%), and f

113 3 or higher adverse event across groups was neutropenia (53 [30%] of 178 patients in the acalabrutin

114 ts compared with carboplatin-paclitaxel (eg, neutropenia [54% vs 23%; P < .001] and grade 3/4 nausea/

115 gic toxicities during induction were febrile neutropenia (55%) and sepsis (35%).

116 neutropenia (47 [15%] vs 92 [30%]), febrile neutropenia (57 [18%] vs 34 [11%]), leucopenia (22 [7%]

117 t 1 adverse event, the most common including neutropenia (57.5% vs 53.3%), peripheral neuropathy (23.

118 the placebo plus paclitaxel group, they were neutropenia (59 [23%] of 259 patients), leucopenia (27 [

119 utropenia (45.8% v 21.5%; P < .001), febrile neutropenia (6.3% v 3.7%; P = .019), and diarrhea (17.8%

120 The most common grade 3/4 toxicities were neutropenia (62%), febrile neutropenia (35%), and periph

121 e adverse event in both treatment groups was neutropenia (73 [32%] in the nintedanib group vs 54 [24%

122 ts were peripheral sensory neuropathy (79%), neutropenia (76%), fatigue (74%), and nausea (71%).

123 s in the olaparib plus paclitaxel group were neutropenia (78 [30%] of 262 patients), leucopenia (42 [

124 e toxicities were fatigue (83% of patients), neutropenia (79%), anemia (63%), alopecia (50%), elevate

125 s occurred in 96% of patients, most commonly neutropenia (79%), thrombocytopenia (76%), and anemia (4

126 The most common adverse event was neutropenia (80 [26%] of 312 patients in the GP2013-CVP

127 he most common grade 3-4 adverse events were neutropenia (85 [26%] of 323 patients in the ramucirumab

128 y-cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab

129 (lymphopenia, leukopenia, anemia, 98% each; neutropenia, 93%; and thrombocytopenia, 84%).

130 The most common toxicities were neutropenia (96%), leukopenia (84%), thrombocytopenia (8

131 rring in 5% or more of patients were febrile neutropenia (98 [39%] of 252; five related to treatment)

132 ectronic medical record was used to identify neutropenia (absolute neutrophil count <1500 cells/mm(3)

133 rade 1 or 2 toxicities were nausea, fatigue, neutropenia, alopecia, dizziness, and dyspnea.

134 (95% CI 10-18) for patients with grade >= 3 neutropenia and 10 months (95% CI 8-13) for patients wit

135 hs (95% CI 5-8) for patients with grade >= 3 neutropenia and 6 months (95% CI 5-6) for patients with

136 mors protected them from doxorubicin-induced neutropenia and anemia while retaining antitumor efficac

137 ciated with well-established factors such as neutropenia and corticosteroid exposure.

138 n (SOT) but is associated with high rates of neutropenia and delayed-onset postprophylaxis disease.

139 provided clinically relevant descriptions of neutropenia and fatigue trajectories caused by lenalidom

140 , 0.65 to 1.53) and the incidence of grade 4 neutropenia and febrile neutropenia favored pazopanib.

141 Neutropenia and febrile neutropenia were key secondary e

142 ents occurred in 11 (10%) patients, of which neutropenia and febrile neutropenia were the most common

143 78 were significantly more likely to develop neutropenia and have to stop clozapine treatment (OR = 2

144 ological toxicity, as well as the absence of neutropenia and improved overall tolerability in multipl

145 0.07); events were related mainly to febrile neutropenia and infection.

146 t 4 cycles in the RR-CHOP-14 arm, especially neutropenia and infections.

147 Neutropenia and neutrophil dysfunction cause serious inf

148 es, was successfully repurposed for treating neutropenia and neutrophil dysfunction in the rare inher

149 A higher incidence of neutropenia and pneumonia was observed in the daratumuma

150 Febrile neutropenia and sensory neuropathy incidences were simil

151 fic diagnostic and therapeutic challenges in neutropenia and solid organ and hematopoietic stem cell

152 The association between fever and neutropenia and the risk for life-threatening infections

153 Durations of severe neutropenia and thrombocytopenia were prolonged in the i

154 Neutropenia and thrombocytopenia were the most frequent

155 eservoirs, resulted in more frequent grade 4 neutropenia and thrombocytopenia, and did not affect sur

156 de 3 or 4 adverse events in both groups were neutropenia and thrombocytopenia.

157 the subcutaneous daratumumab group (febrile neutropenia) and four in the intravenous group (sepsis [

158 imen (especially in patients with protracted neutropenia), and how long to continue antimicrobial the

159 ed a transfusion, three patients had grade 3 neutropenia, and 1 patient had grade 4 thrombocytopenia.

160 strointestinal complaints, thrombocytopenia, neutropenia, and aminotransferase elevations.

161 eficiency, common variable immunodeficiency, neutropenia, and immune dysregulation, polyendocrinopath

162 equency and severity of neutropenia, febrile neutropenia, and infections.

163 yed intrauterine growth retardation, chronic neutropenia, and NK cell deficiency.

164 (and postnatal) growth retardation, chronic neutropenia, and NK cell deficiency.

165 prolonged grade 3 thrombocytopenia, grade 4 neutropenia, and pleural effusion.

166 rs plus gastrointestinal disturbance, severe neutropenia, and prior beta-lactam antibiotic use.

167 lus platinum-etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enteroco

168 emotherapy regimen and included lymphopenia, neutropenia, and thrombocytopenia (21 [100%] patients fo

169 V, but HIV remains a risk factor for anemia, neutropenia, and thrombocytopenia and requires ongoing a

170 2.0 (95% confidence interval [CI], 1.4-3.0); neutropenia aOR, 6.3 (95% CI, 2.0-19.6); and thrombocyto

171 lating factor) in shortening the duration of neutropenia, as well as with the discovery of more targe

172 ent, there is no consensus regarding whether neutropenia at the time of port placement confers a high

173 splenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation,

174 One patient experienced febrile neutropenia but was able to complete paclitaxel on time.

175 ervention in critically ill patients without neutropenia, but the quality of the evidence is low.

176 Myelokathexis is neutropenia caused by neutrophil retention in bone marro

177 f KPC-Kp bacteremia identified septic shock, neutropenia, Charlson comorbidity index >=3, and recent

178 A cluster of cefepime-induced neutropenia (CIN) was identified from June 2017 to May 2

179 Interestingly, mice with neutropenia, defective neutrophil infiltration or lackin

180 Experimental neutropenia during acute pyelonephritis resulted in a co

181 he primary endpoints were duration of severe neutropenia during cycle 1 and the occurrence of severe

182 during cycle 1 and the occurrence of severe neutropenia during the treatment period.

183 ntibiotic cycling-based strategy for febrile neutropenia effectively reduced carbapenem use, which ma

184 In 937 febrile, nonsevere neutropenia episodes, frequencies of low-, intermediate-

185 uded nausea, diarrhea, constipation, febrile neutropenia, fatigue, hypokalemia, decreased appetite, a

186 incidence of grade 4 neutropenia and febrile neutropenia favored pazopanib.

187 bility and reduced frequency and severity of neutropenia, febrile neutropenia, and infections.

188 common being weight increase (ten [8%]) and neutropenia (five [4%]).

189 [2%]) in the quizartinib group, and febrile neutropenia (five [5%]), sepsis or septic shock (four [4

190 atients) were pneumonia (five [6%]), febrile neutropenia (five [6%]), pulmonary embolism (three [4%])

191 ) in oncohematological patients with febrile neutropenia (FN) and its impact on mortality.

192 even [44%] of 16), hypokalaemia (six [38%]), neutropenia (four [25%]), thrombocytopenia (four [25%]),

193 compared with pneumonia (four [4%]), febrile neutropenia (four [4%]), anaemia (three [3%]), and neutr

194 and pneumonitis (two [3%]); and in group C, neutropenia (four [6%]) and pleural effusion (two [3%]).

195 ]), fatigue (five [8%]), nausea (four [7%]), neutropenia (four [7%]), and vomiting (three [5%]).

196 Patients with neutropenia had a port infection-related death rate of 0

197 Results Ports placed in patients with neutropenia had an infection-related removal rate of 3.8

198 cies, peri-COVID-19 lymphopenia, or baseline neutropenia had worse COVID-19 outcomes.

199 Additionally, neutropenia has been associated with increased susceptib

200 iples related to the management of fever and neutropenia have responded to changes in the patients at

201 .004), infiltrates (HR 3.08, P = 0.032), and neutropenia (HR 1.15, P = 0.04).

202 common grade 3 or worse adverse events were neutropenia in 161 (60%) patients, anaemia in 101 (37%),

203 ombocytopenia in 48 (84%) of 57 patients and neutropenia in 45 (79%) of 57 patients.

204 uding thrombocytopenia in 63 (74%) patients, neutropenia in 53 (62%), and anaemia in 41 (49%).

205 anhydroglucitol-6-phosphate (1,5AG6P) caused neutropenia in a glucose-6-phosphatase 3 (G6PC3)-deficie

206 paclitaxel only if patients had had febrile neutropenia in a prior cycle or at investigator discreti

207 Conclusion Neutropenia in adults at the time of implantable subcuta

208 erogenic effects are however counteracted by neutropenia in circulation and plaque.

209 y fibrosis in group B and one due to febrile neutropenia in group C.

210 In conclusion, we show that the neutropenia in patients with G6PC3 or G6PT mutations is

211 occurs after chemotherapy-induced prolonged neutropenia in patients with hematological malignancies.

212 common grade 3-4 adverse events were febrile neutropenia in seven (14%) patients, decreased neutrophi

213 limumab group (16 [5%] of 340 patients), and neutropenia in the chemotherapy group (66 [21%] of 313 p

214 patients), thrombocytopenia (in 28.7%), and neutropenia (in 12.8%).

215 de 3-4 palbociclib-related adverse event was neutropenia (in 21 [34%] of 62 patients).

216 s of grade 3 or higher during treatment were neutropenia (in 78% of the patients), anemia (in 43%), a

217 ommon events of grade 3 or higher, including neutropenia (in 85% of the patients), leukopenia (in 58%

218 bocytopenia, autoimmune hemolytic anemia, or neutropenia, in addition to splenomegaly, generalized or

219 ctively investigated the association between neutropenia induced by first-line Nab-Gem and survival i

220 al hematopoietic progenitors, preventing the neutropenia induced by treatment with dual CDK4/6 inhibi

221 tients; nine [3%] vs no patients had febrile neutropenia), infections (86 [31%] vs 48 [18%]), and thr

222 Neutropenia is a common side effect associated with nab-

223 Nab-Gem-induced neutropenia is associated with longer survival in metast

224 These 3 patients shared congenital neutropenia linked with various other SDS phenotypes.

225 on is an independent risk factor for anemia, neutropenia, lymphocytopenia, and thrombocytopenia.

226 lated adverse events were transient: grade 4 neutropenia (n = 2 patients) and thrombocytopenia (n = 1

227 s high-dose vs standard-dose vitamin D3 were neutropenia (n = 24 [35%] vs n = 21 [31%], respectively)

228 related adverse events; the most common were neutropenia (n = 9), thrombocytopenia (n = 3), and perip

229 s were manageable with the most common being neutropenia (n=10 [22%]) and cellulitis (n=6 [13%]).

230 d in the methotrexate-vinblastine group were neutropenia (n=10, 45%) and liver transaminitis (n=4, 18

231 e most comment grade 3-4 adverse events were neutropenia (n=2 [5%]), hypertension (n=2 [5%]), insomni

232 adverse events were thrombocytopenia (n=58), neutropenia (n=31), anaemia (n=28), fatigue (n=14), hypo

233 s 3 or 4 neutropenia (n=79, 47%) and febrile neutropenia (n=49, 29%).

234 vents included infections with grades 3 or 4 neutropenia (n=79, 47%) and febrile neutropenia (n=49, 2

235 se 2 single-agent cohort of 13 patients were neutropenia (nine [69%]) and thrombocytopenia (eight [62

236 ated with mild cases of thrombocytopenia and neutropenia, none of which was grade 3 or higher.

237 Febrile neutropenia occurred in 16% of cycles, and tumor lysis s

238 Grade 3/4 neutropenia occurred in 19% of patients.

239 Grade 3 or 4 neutropenia occurred in 52.8% of patients in the venetoc

240 Severe neutropenia occurred in nine (26%) of 34 patients in gro

241 cluded one (3%) patient with grade 3 febrile neutropenia, one (3%) patient with grade 4 hyperglycaemi

242 se event (ten [11%] events), and anaemia and neutropenia or febrile neutropenia were the most frequen

243 ild and/or manageable and most commonly were neutropenia or GI events.

244 ients, based on the IMI rate and presence of neutropenia or steroid use.

245 ients, based on the IMI rate and presence of neutropenia or steroid use.

246 wo groups, and there were no cases of severe neutropenia or thrombocytopenia.

247 ) scale, and no evidence of iron deficiency, neutropenia, or abnormal hepatic or renal function, were

248 ents within 1 month, patients with high-risk neutropenia, or patients with indwelling catheters at th

249 ersus 0.91% (22 of 2421) in patients without neutropenia (P = .003).

250 thrombocytopenia (P = .299 vs controls) and neutropenia (P = .112 vs controls) were unaffected by NA

251 s 0.12% (three of 2421) for patients without neutropenia (P = .22).

252 hs (95% CI 8-13) for patients with grade < 3 neutropenia (p = 0.04; HR 0.44).

253 0.02), prior cancer treatment (P=0.023), and neutropenia (P<0.0001) were identified as independent ri

254 prior use of corticosteroids (P=0.021), and neutropenia (P<0.001) were independent risk factors for

255 ths (95% CI 5-6) for patients with grade < 3 neutropenia [p = 0.08; hazard ratio (HR 0.68)].

256 ted only in severe congenital and idiopathic neutropenia patients.

257 The most common grade 3-4 adverse event was neutropenia (R/R, 58% of patients; 1L, 53%).

258 The incidence of grade 3-4 neutropenia ranged from eight (18%) of 45 patients with

259 D-Kd was well tolerated with low neutropenia rates, and it demonstrated deep responses an

260 Neutropenia represents an important problem in patients

261 Severe congenital neutropenia (SCN) evolves to secondary myelodysplastic s

262 Severe congenital neutropenia (SCN) is characterized by a near absence of

263 The molecular cause of severe congenital neutropenia (SCN) is unknown in 30% to 50% of patients.

264 rate mouse models of human severe congenital neutropenia (SCN) using patient-derived mutations in the

265 11 [25%]), leukopenia (seven [16%]), febrile neutropenia (seven [16%]), and pneumonia (seven [16%]).

266 riate analysis, the occurrence of grade >= 3 neutropenia showed a statistically significant associati

267 8%] vs two [3%]), anaemia (seven [5%] vs 0), neutropenia (six [5%] vs three [4%]), and increased alan

268 e adult populations, including patients with neutropenia, solid organ transplants, and nonurologic su

269 m three unrelated pedigrees characterized by neutropenia, specific granule deficiency, myelodysplasia

270 s), thrombocytopenia (14 [17%]), and febrile neutropenia (ten [12%]).

271 ue or asthenia (eight [4%] vs two [2%]), and neutropenia (ten [5%] vs four [4%]).

272 unit: monthly antibiotic cycling for febrile neutropenia that included cefepime (+/- metronidazole) a

273 Aside from increased neutropenia, the safety profile of daratumumab plus pom-

274 penia (four [4%]), anaemia (three [3%]), and neutropenia (three [3%]) in the taxane group.

275 ents included thrombocytopenia (three [3%]), neutropenia (three [3%]), and anaemia (two [2%]).

276 re increased lipase (three [7%]) and febrile neutropenia (three [7%]).

277 penia (15 [41%]) in the pazopanib group, and neutropenia (three [9%] of 35 patients) and febrile neut

278 enia (three [9%] of 35 patients) and febrile neutropenia (three [9%]) in the control group.

279 h the most common were anaemia (four [12%]), neutropenia (three [9%]), and pancreatitis (two [6%]).

280 Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred

281 ng approaches to the management of fever and neutropenia through observational and controlled clinica

282 events; of which the most common events were neutropenia (trebananib 238 [35%] vs placebo 126 [38%])

283 ng sarcoma, four [9%] for osteosarcoma), and neutropenia (two [4%] for Ewing sarcoma, four [9%] for o

284 During cycle 1, mean duration of severe neutropenia was 0.8 day (SD 2.4) in group 1, 1.5 days (3

285 Neutropenia was categorized using the National Cancer In

286 Grade 3 or 4 neutropenia was experienced by 66% of patients, with mor

287 Incidence of neutropenia was higher with zanubrutinib, although grade

288 Treatment-related febrile neutropenia was reported in 10% of patients.

289 ed with maribavir, and a higher incidence of neutropenia was reported with valganciclovir.

290 One grade 3 event (neutropenia) was possibly treatment-related.

291 e serious adverse event (ie, grade 4 febrile neutropenia) was reported.

292 notably dysgeusia - and a lower incidence of neutropenia were found in the maribavir group.

293 Neutropenia and febrile neutropenia were key secondary end points.

294 hematopoietic stem cell transplantation, and neutropenia were not.

295 Episodes of neutropenia were of short duration.

296 ) patients, of which neutropenia and febrile neutropenia were the most common (five [5%] patients for

297 nts), and anaemia and neutropenia or febrile neutropenia were the most frequent grade 3 or worse even

298 itis, asymptomatic anaemia, and asymptomatic neutropenia) were considered related to dolutegravir.

299 ed in 20 participants (including 40% who had neutropenia) who were colonized by a median of 2 (range,

300 use four of six patients experienced grade 4 neutropenia with grade 4 thrombocytopenia also occurring